Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 4531858, 4 pages
https://doi.org/10.1155/2017/4531858
Case Report

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction

1Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
2College of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
3Division of Hematology and Oncology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA

Correspondence should be addressed to Joselle Cook; ude.etatsnwod@kooc.ellesoj

Received 18 March 2017; Accepted 4 June 2017; Published 6 July 2017

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2017 Joselle Cook et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. F. Low, N. H. M. Tap, T. Y. Kew, C. S. Ngiu, and R. Sridharan, “Non secretory multiple myeloma with extensive extramedullary plasmacytoma: A diagnostic dilemma,” Iranian Journal of Radiology, vol. 12, no. 3, Article ID e11760, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Bladé, C. Fernández de Larrea, L. Rosiñol, M. T. Cibeira, R. Jiménez, and R. Powles, “Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach,” Journal of Clinical Oncology, vol. 29, no. 28, pp. 3805–3812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, and M. Lazzarino, “Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients,” Annals of Oncology, vol. 21, no. 2, pp. 325–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Wu, F. E. Davies, K. Boyd et al., “The impact of extramedullary disease at presentation on the outcome of myeloma,” Leukemia and Lymphoma, vol. 50, no. 2, pp. 230–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Schols and L. L. Tick, “Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: A case report,” Journal of Medical Case Reports, vol. 9, no. 37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Touzeau and P. Moreau, “How i treat extramedullary myeloma,” Blood, vol. 127, no. 8, pp. 971–976, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Bladé, C. F. de Larrea, and L. Rosiñol, “Extramedullary involvement in multiple myeloma,” Haematologica, vol. 97, no. 11, pp. 1618-1619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Roccaro, Y. Mishima, A. Sacco et al., “CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation,” Cell Reports, vol. 12, no. 4, pp. 622–635, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Z. Usmani, C. Heuck, A. Mitchell et al., “Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents,” Haematologica, vol. 97, no. 11, pp. 1761–1767, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ajay and C. Abhinav, “A multiple myeloma patient presenting with multiple hepatic masses,” Journal of Medical Cases, pp. 673–675, 2013. View at Google Scholar
  11. M. Cavo, E. Terpos, C. Nanni et al., “Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group,” The Lancet Oncology, vol. 18, no. 4, pp. e206–e217, 2017. View at Publisher · View at Google Scholar
  12. L. Rosiñol, A. Oriol, A. I. Teruel et al., “Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study,” Blood, vol. 120, no. 8, pp. 1589–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Raanani, O. Shpilberg, and I. Ben-Bassat, “Extramedullary disease and targeted therapies for hematological malignancies—Is the association real?” Annals of Oncology, vol. 18, no. 1, pp. 7–12, 2007. View at Publisher · View at Google Scholar · View at Scopus